Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease
- PMID: 25447229
- DOI: 10.1016/j.nbd.2014.10.017
Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease
Abstract
l-3, 4-dihydroxyphenylalanine (L-DOPA) is the most effective treatment for Parkinson's disease but can induce debilitating abnormal involuntary movements (dyskinesia). Here we show that the development of L-DOPA-induced dyskinesia in the rat is accompanied by upregulation of an inflammatory cascade involving nitric oxide. Male Wistar rats sustained unilateral injections of 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle. After three weeks animals started to receive daily treatment with L-DOPA (30 mg/kg plus benserazide 7.5 mg/kg, for 21 days), combined with an inhibitor of neuronal NOS (7-nitroindazole, 7-NI, 30 mg/kg/day) or vehicle (saline-PEG 50%). All animals treated with L-DOPA and vehicle developed abnormal involuntary movements, and this effect was prevented by 7-NI. L-DOPA-treated dyskinetic animals exhibited an increased striatal and pallidal expression of glial fibrillary acidic protein (GFAP) in reactive astrocytes, an increased number of CD11b-positive microglial cells with activated morphology, and the rise of cells positive for inducible nitric oxide-synthase immunoreactivity (iNOS). All these indexes of glial activation were prevented by 7-NI co-administration. These findings provide evidence that the development of L-DOPA-induced dyskinesia in the rat is associated with activation of glial cells that promote inflammatory responses. The dramatic effect of 7-NI in preventing this glial response points to an involvement of nitric oxide. Moreover, the results suggest that the NOS inhibitor prevents dyskinesia at least in part via inhibition of glial cell activation and iNOS expression. Our observations indicate nitric oxide synthase inhibitors as a therapeutic strategy for preventing neuroinflammatory and glial components of dyskinesia pathogenesis in Parkinson's disease.
Keywords: 6-OHDA lesion; GFAP; Glial cells; Neuroinflammation; OX-42; iNOS.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.Exp Neurol. 2016 Dec;286:83-92. doi: 10.1016/j.expneurol.2016.09.013. Epub 2016 Sep 30. Exp Neurol. 2016. PMID: 27697481
-
Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/deltaFosB expression.Neurosci Lett. 2013 Apr 29;541:126-31. doi: 10.1016/j.neulet.2013.02.015. Epub 2013 Feb 18. Neurosci Lett. 2013. PMID: 23428503
-
Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.Neuroscience. 2009 Mar 31;159(3):927-35. doi: 10.1016/j.neuroscience.2009.01.034. Epub 2009 Jan 23. Neuroscience. 2009. PMID: 19302833
-
l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?Synapse. 2016 Dec;70(12):479-500. doi: 10.1002/syn.21941. Epub 2016 Sep 27. Synapse. 2016. PMID: 27618286 Review.
-
Role of nitric oxide in motor control: implications for Parkinson's disease pathophysiology and treatment.Curr Pharm Des. 2011;17(5):471-88. doi: 10.2174/138161211795164176. Curr Pharm Des. 2011. PMID: 21375483 Review.
Cited by
-
ATP Signaling Controlling Dyskinesia Through P2X7 Receptors.Front Mol Neurosci. 2020 Aug 7;13:111. doi: 10.3389/fnmol.2020.00111. eCollection 2020. Front Mol Neurosci. 2020. PMID: 32848592 Free PMC article.
-
Contributive Role of TNF-α to L-DOPA-Induced Dyskinesia in a Unilateral 6-OHDA Lesion Model of Parkinson's Disease.Front Pharmacol. 2021 Jan 11;11:617085. doi: 10.3389/fphar.2020.617085. eCollection 2020. Front Pharmacol. 2021. PMID: 33510643 Free PMC article.
-
4'-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: Contribution of anti-inflammatory and anti-glutamatergic mechanisms.Neuropharmacology. 2024 Jun 15;251:109926. doi: 10.1016/j.neuropharm.2024.109926. Epub 2024 Mar 28. Neuropharmacology. 2024. PMID: 38554815 Free PMC article.
-
Tianqi pingchan granule promotes recovery of glymphatic system function in a rat model of l-DOPA-induced dyskinesia.J Tradit Complement Med. 2024 Apr 29;15(4):380-387. doi: 10.1016/j.jtcme.2024.04.010. eCollection 2025 Jul. J Tradit Complement Med. 2024. PMID: 40677540 Free PMC article.
-
Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.Neurotox Res. 2020 Jan;37(1):12-29. doi: 10.1007/s12640-019-00109-8. Epub 2019 Oct 22. Neurotox Res. 2020. PMID: 31637586 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous